NEWARK, Del, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The genome editing market is predicted to reach US$ 6.2 billion by 2024. The market size is expected to reach US$ 26.5 billion by 2034, projected at a CAGR of 15.7%. The CRISPR-Cas9 genetic editing technology opens up the possibility of correcting or modifying genes that cause genetic disorders. A potential breakthrough in treating cancer may be possible with the use of genome editing, which enables the targeting and modification of cancer cells.
With genome editing, crops can be developed that produce more, are more resistant to pests, and have higher nutritional values. A healthier and more productive livestock can be produced by editing its genome.
The genome editing process facilitates identifying and validating potential drug targets, which facilitates the discovery and development of new drugs. A more effective and targeted drug can be developed through improved methods for editing cell lines.
Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-19118
As genome-editing technologies have evolved in recent years, investigators have been able to rapidly and economically modify a variety of species' genomes with sequence-specific modifications. Scientists can conduct gene editing experiments and studies using CRISPR-based research tools. Researchers and biotech companies can use these companies to edit genomes custom-made for their needs.
Genetic diseases and predispositions can be detected using genome editing technologies. A personalized treatment plan based on an individual's genetic profile can be developed as a result of advances in genome editing. In the past two decades, genome editing has revolutionized the field of biomedicine through its robust editing technology.
Various disease-resistance models can be generated using it at the genetic level to unravel the mechanisms of human disease. The program develops a powerful tool for creating genetically modified organisms that can be used for treating and preventing diseases.
Licensing genome editing technologies can generate revenue for companies with strong intellectual property portfolios. Through genome editing, tissues and organs can be engineered for transplantation in regenerative medicine.
“Increasing research and development studies and investments in gene therapies are expected to drive demand for genome editing. A new generation of technologies and innovative tools will drive the market,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
Key Takeaways from the Market Study:
- The meganucleases segment is projected to expand at 15.6% CAGR by 2034.
- The United States is estimated to register at a CAGR of 15.9% by 2034.
- Between 2019 and 2023, Japan's market experienced a 21.9% CAGR.
- China is experiencing rapid growth, predicted at a CAGR of 16.2% by 2034.
- The ex-vivo segment is anticipated to expand at 15.3% CAGR by 2034.
Act Now to Explore In-Depth Market Analysis: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/19118
Genome Editing Market Report Scope:
| Attributes | Details | ||
| Estimated Market Size in 2024 | US$ 6.2 billion | ||
| Projected Market Valuation in 2034 | US$ 26.5 billion | ||
| Value-based CAGR 2024 to 2034 | 15.7% | ||
| Forecast Period | 2024 to 2034 | ||
| Historical Data Available for | 2019 to 2023 | ||
| Market Analysis | Value in US$ billion | ||
| Key Regions Covered |
| ||
| Key Market Segments Covered |
| ||
| Key Countries Profiled |
|
| |
| Key Companies Profiled |
| ||
Request Report Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-19118
Competitive Landscape:
Global and regional players dominate the genome editing market. The companies focus on developing tools, innovative technologies, and marketing strategies to attract consumers and increase market share.
Globally, the leading players are focusing their investments on the development of new tools for genome engineering to address the increasing demand for research. The research area in genomics is expected to develop rapidly due to the rapid advancement of several molecular techniques.
Some of the key developments are:
- In February 2022, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. reported positive interim results from their ongoing Phase 1 clinical study of NTLA-2001, an in vivo genome editing candidate slated to treat transthyretin (ATTR) amyloidosis.
Genome Editing - Key Segments:
By Technology:
- Meganucleases
- CRISPR/Cas9
- TALENs/MegaTALs
- ZFN
- Others
By Delivery:
- Ex-vivo
- In-vivo
By Mode:
- Contract
- In-house
By End User:
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
- Contract Research Organizations
By Application:
- Genetic Engineering
- Cell Line Engineering
- Animal Genetic Engineering
- Plant Genetic Engineering
- Others
- Clinical Applications
- Diagnostics
- Therapy Development
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage in the Healthcare Market Insights Domain:
Personal Genome Testing Market Size: The global market is forecast to be appraised at US$ 4,468 Million by 2032, up from US$ 1,545.5 Million in 2022, advancing at a CAGR of 10.1% during the forecast period.
Whole Genome Amplification Market Share: The market valuation is expected to surpass US$ 5.5 Billion by the end of 2033, reports Future Market Insights (FMI) in its market analysis. In 2023, sales of whole genome amplification are likely to reach US$ 2.8 Billion. The global whole genome amplification market is projected to record a dynamic 7.0% CAGR between 2023 and 2033.
Orthopedic Braces and Support Market Demand: The global market is assessed to surpass a valuation of US$ 4.6 billion by 2024 and is projected to reach a value of US$ 8.8 billion by 2034, reflecting a CAGR of 6.7% over the assessment period.
Medical Exoskeleton Market Outlook: The market value is estimated to be US$ 394.3 million in 2024. Global population aging is on the rise, creating a greater need for assistive exoskeleton devices for regular activities or rehabilitation. The market is predicted to rise at a robust CAGR of 29.1% during the forecast period. The global medical exoskeleton industry's share is estimated to reach a value of nearly US$ 5,100 million by 2034.
Needle-Free Injection System Market Growth: The global market is predicted to grow to US$ 667 million by 2034 from US$ 158 million in 2024. The market is expected to increase at an astounding 15.5% compound annual growth rate between 2024 and 2034.
Veterinary Telemedicine Market Opportunity: The market is estimated to reach a valuation of US$ 145 million in 2024. It is projected to reach a value of US$ 746 million by 2034, reflecting a CAGR of 17.8% over the assessment period
Cardiology Information System Market Forecast: The market is estimated to be valued at US$ 1.3 billion in 2024. The cardiology information system is predicted to rise at a CAGR of 9.7% from 2024 to 2034. The global cardiology information system market is anticipated to reach US$ 3.7 billion by 2034.
ePrescibing Market Trends: The market is expected to grow at a CAGR of 27.1% during the projected period. The market value is projected to increase from US$ 4.8 billion in 2024 to US$ 52.2 billion by 2034.
Pharmaceutical Manufacturing Equipment Market Overview: The global market is expected to rise at a CAGR of 6.4% during the projected period. The market value is projected to increase from US$ 14.7 billion in 2024 to US$ 27.3 billion by 2034.
Medical Display Market Development: The global market size is anticipated to be worth US$ 4.3 billion by 2034. According to the estimates, the market is projected to clock a 5.3% CAGR until 2034. In 2024, the medical display market size is valued at US$ 2.6 billion.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
